Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Reported Earlier, Cardiol Therapeutics Says First Patient Enrolled In Phase 2 Study Of CardiolRx For Pericarditis

Author: Benzinga Newsdesk | January 17, 2023 04:05pm

Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients with recurrent pericarditis. Elsley told Proactive the study is designed to evaluate improvement in objective measures of disease and assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx. The study is expected to enroll 25 patents.

Posted In: CRDL